d*p
发帖数: 534 | 1 http://www.nejm.org/doi/full/10.1056/NEJMoa1106152
这几天太忙，没来得及转，在DC immunotherapy 会议上他们就报告了， 非常的
exciting. | n********k
发帖数: 2818 | 2 not in the field...a bit surprised how far people have gone into the
clinical testing but this is a perfect example how a routine tech in a basic
research area could turn into something exciting/useful in a clinical
setting...if my memory is right, this iCap strategy has been around at least
a decade and is widely used in animal study for various purpose...
【在 d*p 的大作中提到】
: http://www.nejm.org/doi/full/10.1056/NEJMoa1106152
: 这几天太忙，没来得及转，在DC immunotherapy 会议上他们就报告了， 非常的
: exciting.
| d*p
发帖数: 534 | 3 Idea is not new, but make it happen in human is very exciting. Clean 90%
cells in 4 hours. 24 hours, all active cells will be cleaned. The safety of
cell therapy will no longer be a big issue now. | n********k
发帖数: 2818 | 4 The safety of cell therapy will no longer be a big issue now.
Maybe true for certain treatments but generally speaking, I bet this is by
far a too bold statement and is bound to be wrong...for those issues of
tumorigenic nature, it would still stand. Otherwise we would have cured
cancers, right? capases related pathways have proven to have somewhat
limited usages in cancer treatments and tumor cells have evolved ways to
escape from it...and some of the early ones functioned in a way other than
as expected...I would be cautiously excited...
of
【在 d*p 的大作中提到】
: Idea is not new, but make it happen in human is very exciting. Clean 90%
: cells in 4 hours. 24 hours, all active cells will be cleaned. The safety of
: cell therapy will no longer be a big issue now.
| d*p
发帖数: 534 | 5 I guess you don't have much background of cell therapy. So far, only the
therapy with the Y-chain recovery in stem cell is oncogenic, and the main
reason is because strong signal of Y chain itself induces lymphoma instead
of the viral integration. For all the T cell or DC therapies which have been
in clinical for a long time, 0 case with lymphoma.
Well, I still agree with you on the concerns of using in stem cell
therapy. For my understanding, once the stem cell in the therapy will not
produce T/B cell, which usually go through somatic recombination due to TCR,
BCR rearrange, with a lot of DNA broken, the major oncogenic reason, I won'
t worry too much about the safety now. | n********k
发帖数: 2818 | 6 Are u talking about stem cell therapy in general or more about in immuno-
lineage? Seems to me, you are referring to the T cell or DC therapies etc..
.BTW, I have no experiences with cell therapy except from research point of
view...and I am not working in blood-related lineages either...
the
been
TCR,
won'
【在 d*p 的大作中提到】
: I guess you don't have much background of cell therapy. So far, only the
: therapy with the Y-chain recovery in stem cell is oncogenic, and the main
: reason is because strong signal of Y chain itself induces lymphoma instead
: of the viral integration. For all the T cell or DC therapies which have been
: in clinical for a long time, 0 case with lymphoma.
: Well, I still agree with you on the concerns of using in stem cell
: therapy. For my understanding, once the stem cell in the therapy will not
: produce T/B cell, which usually go through somatic recombination due to TCR,
: BCR rearrange, with a lot of DNA broken, the major oncogenic reason, I won'
: t worry too much about the safety now.
| d*p
发帖数: 534 | 7 I am talking about general cell therapy. Oncogenic is only one part of the
safety issue. For example, one major concern of T cell therapy is over-
activated T cell might cause autoimmune disease, which is a very common
problem in stem cell and organ transplant, including cancer immunotherapy.
Rosenberg, a big name in cancer immune therapy, killed one patient due to
the infused Her2/neu targeting T cell were activated in lung.
Stem cell therapy actually only account for a small part of cell therapy.
Again, as I said, once the stem cell is not for T/B cell reconstitution, the
oncogenic possibility is very very low. 0 report from clinical so far. Even
the purpose of stem cell therapy is to reconstitute the hematological
system, it will have better security with this technology, given cas9 is
quite downstream of the apoptotic signal pathway.
Whatever, we would not expect this technology will figure out everything | n*********b
发帖数: 140 | 8 This seems to be a solid clinical trial for an old concept.
But the scope of the problem seems to be limited. It begins with some
negative effects of donor T cells during HSCT, which seems to be manageable
through many other means. Specifically, if one can produce a cocktail of
cytokines there will be no such a problem to begin with.
Having said that, the real application of this technique may be at the
controlled differentiation after stem cell transplantation. | n********k
发帖数: 2818 | 9 Maybe I am just not well informed: has anyone clarified on the neural stem
transplantation case last year....I thought there was tumor formation four
ys after the neural stem cell transplanation for the kid, and some of
experts' argument against were pretty lame I would say...I don't know how
much experience we have so far over stem cell therapy and do we really have
a decent handle of the potential for tumors, beyond some other problems you
have listed?
the
Even
【在 d*p 的大作中提到】
: I am talking about general cell therapy. Oncogenic is only one part of the
: safety issue. For example, one major concern of T cell therapy is over-
: activated T cell might cause autoimmune disease, which is a very common
: problem in stem cell and organ transplant, including cancer immunotherapy.
: Rosenberg, a big name in cancer immune therapy, killed one patient due to
: the infused Her2/neu targeting T cell were activated in lung.
: Stem cell therapy actually only account for a small part of cell therapy.
: Again, as I said, once the stem cell is not for T/B cell reconstitution, the
: oncogenic possibility is very very low. 0 report from clinical so far. Even
: the purpose of stem cell therapy is to reconstitute the hematological
|
|
